|
The three-month suspension began last Wednesday
and, according to a WADA statement, is a result of "WADA's
quality assessment procedures that identified non-conformities
with best practice."
Los Angeles is competing against Paris to host the 2024 Olympics
and the local bid committee has selected UCLA as the site for
the Olympic Village, which would house all competing athletes.
During the suspension, the UCLA laboratory can carry out all its
regular anti-doping activities, but it must obtain a second
opinion from another WADA-accredited lab prior to reporting any
adverse analytical finding for the glucocorticoids
"prednisolone" and "prednisone"; and, the anabolic steroids
"boldenone" and "boldione".
WADA said suspensions limited to certain substances have been
issued in the past and allow for appropriate monitoring of the
lab to ensure full implementation of necessary improvements with
the objective of a return to full compliance.
An independent WADA Disciplinary Committee advised by WADA's
Laboratory Expert Group delivered its recommendation for a
limited suspension on June 14.
The UCLA lab was notified of the decision two days later and has
21 days to appeal the decision to the Court of Arbitration for
Sport.
As part of the process, WADA will conduct a site visit within a
timeframe that reasonably allows the UCLA Laboratory to finalize
implementation of all remedial actions.
(Reporting by Frank Pingue in Toronto; Editing by Toby Davis)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
